PDZK1IP1 and pancreatic neoplasm: This study also aimed to investigate if MAP17-expressing cells have a higher NAD pool, and if the depletion of this pool by Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors could sensitize cells to classic chemotherapy in pancreatic tumor xenografts.